| ²é¿´: 326 | »Ø¸´: 0 | ||
liuyizhen_ľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
FDAÖзÒëÇóÖú
|
|
Angiomax with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as listed in the REPLACE-2 trial is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI). Angiomax is indicated for patients with, or at risk of, heparin induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing PCI. |
» ²ÂÄãϲ»¶
281Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
»ªÄÏÀí¹¤0703»¯Ñ§£¬×Ü·Ö336Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ13È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
²ÄÁÏÓ뻯¹¤×¨Ë¶306·ÖÕÒºÏÊʵ÷¼Á
ÒѾÓÐ3È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ11È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
319Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´















»Ø¸´´ËÂ¥